HEALTH SII's Covovax Receives Emergency Use Approval for Adults, Children Over 12 DCGI has granted EUA to Serum Institute of India’s (SII) Covid-19 vaccine ‘Covovax’ for adults and for children above the age of 12 years.
HEALTH Bharat Biotech submits Covaxin trial data for ages 2-18 to DCGI: Report Covid-19 vaccine Covaxin manufacturer Bharat Biotech has submitted the trial data for children in the 2-18 years age group to the DCGI.
HEALTH Single-Dose Sputnik Light gets approval for phase 3 trial The single-dose COVID-19 vaccine Sputnik Light received approval from SEC of the Drugs Controller General of India.
HEALTH DCGI gives nod for conducting study on mixing vaccines The Drugs Controller General of India (DCGI) approved a study on mixing Covaxin and Covishield Covid-19 vaccines in India on Tuesday.
HEALTH Zydus Cadila applies for emergency use nod for COVID-19 vaccine The pace of the second wave of coronavirus in the country is now slowing down. The country is being vaccinated rapidly amid fears of a third wave of the pandemic. Drug maker Zydus Cadila on Thursday sought approval for the emergency use of its vaccine.
HEALTH Bharat Biotech submits Phase 3 data for Covaxin Bharat Biotech has submitted phase 3 data to the Drug Controller General of India (DCGI) for their indigenous Covid-19 vaccine, Covaxin, according to Niti Aayog member VK Paul.
HEALTH Covaxin phase II/III clinical trials for 2-18 age group to begin in 10-12 days: Govt Covaxin received the Drugs Controller General of India's (DCGI) nod to conduct clinical trials in children on May 11.
/dnp-english/media/agency_attachments/2024/11/25/2024-11-25t064936166z-dnp-india-logo-640x480-dnp-news-2.png){kind=logo}